Anidulafungin in Treating Immunocompromised Children With Neutropenia

You may be eligible if

• DISEASE CHARACTERISTICS:
• Neutropenia due to cytotoxic chemotherapy or aplastic anemia
• * Duration expected to be 10 days
• * Absolute neutrophil count less than 500/mm\^3 OR less than 1,000/mm\^3 and expected to fall below 500/mm\^3 within 72 hours
• No deeply invasive fungal infection confirmed prior to study entry
• PATIENT CHARACTERISTICS:
• Age
• 2 to 17
• Performance status
• Not specified
• Life expectancy
• Not specified
• Hematopoietic
• See Disease Characteristics
• Hepatic
• AST or ALT no greater than 5 times upper limit of normal (ULN)
• Bilirubin no greater than 2.5 times ULN
• Renal
• Creatinine clearance at least 30 mL/min
• Other
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective barrier contraception during and for at least 30 days after study participation
• No prior anaphylaxis attributed to the echinocandin class of antifungals
• No other concurrent medical condition that would preclude study participation
• PRIOR CONCURRENT THERAPY:
• Biologic therapy
• Not specified
• Chemotherapy
• See Disease Characteristics
• Endocrine therapy
• Not specified
• Radiotherapy
• Not specified
• Surgery
• Not specified
• Other
• More than 4 weeks since prior investigational drugs
• No prior participation in this clinical trial
• No prior anidulafungin
• No other concurrent investigational drugs
• No other concurrent systemic antifungal agents (e.g., amphotericin, systemic azoles, or triazole antifungal agents)
• * Concurrent oral, nonabsorbable azoles and topical antifungal agents (e.g., nystatin and/or azole formulations) allowed
• Concurrent broad-spectrum antibiotics allowed